Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units

Manuel Hidalgo, Elzbieta Izbicka, S. Gail Eckhardt, John R. Macdonald, Cesario Cerna, Lionel Gomez, Eric K. Rowinsky, Steven D Weitman, Daniel D. Von Hoff

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

MGI 114 (6-hydroxymethylacylfulvene, HMAF) is a novel semisynthetic antitumor compound derived from the sesquiterpene mushroom toxin illudin S. Although illudins did not demonstrate significant activity as antiproliferative agents in tumor-bearing animals, several properties including its potent inhibition of DNA synthesis and a unique interaction with DNA led to a structure-activity-based synthetic effort to obtain analogs with improved therapeutic potential. MGI 114 was selected for further development based on its antitumor activity in numerous preclinical tests. MGI 114 was evaluated against adult and pediatric human tumors taken directly from cancer patients and cultured in a human tumor colony-forming assay (HTCFA) to assess the antitumor spectra, concentration-response relationship, schedule dependence and activity of this agent against tumors considered resistant to conventional anticancer drugs. Human tumor colony-forming units were treated with HMAF at concentrations of 0.001, 0.01, 0.1 and 1 μg/ml, both as a 1 h exposure and as a continuous 14 day exposure. A response was scored if there was 50% or less colony survival. In vitro response rates in the range of 50-80% were observed against tumor colony-forming units originating from carcinomas of the colon, kidney, breast, lung cancer, ovary and melanoma. MGI 114 also demonstrated antitumor activity against neuroblastoma colony-forming units. Antitumor activity was not influenced by exposure time as demonstrated by the similar responses rates obtained with the 1 h and continuous exposure at all concentrations tested. However, there was a significant positive concentration-response relationship to both exposure duration with responses increasing from below 10% at the lowest concentration to over 70% at the highest concentration, except for the pediatric tumors on the 1 h exposure for which this relationship was less apparent. At the higher concentration tested, MGI 114 displayed substantial antiproliferative effects in the range of 70% against tumor specimens resistant to classic cytotoxic agents including irinotecan, paclitaxel, 5-fluorouracil, cisplatin, doxorubicin and cyclophosphamide. These results demonstrate that MGI 114 exhibits a broad spectrum of antitumor activity against both adult and pediatric primary tumor colony-forming units in a concentration-dependent manner both at short and prolonged exposure duration. The substantial in vitro activity of MGI 114 at concentrations achievable in clinical trials, together with its activity against tumors resistant to classic standard cytotoxic drugs, justifies the further clinical evaluation of this unique agent.

Original languageEnglish (US)
Pages (from-to)837-844
Number of pages8
JournalAnti-Cancer Drugs
Volume10
Issue number9
StatePublished - 1999

Fingerprint

Stem Cells
Pediatrics
Neoplasms
irinotecan
illudin S
irofulven
Sesquiterpenes
Agaricales
DNA
Cytotoxins
Paclitaxel
Neuroblastoma
Fluorouracil
Pharmaceutical Preparations
Ovarian Neoplasms
Doxorubicin
Cyclophosphamide
Cisplatin
Melanoma
Lung Neoplasms

Keywords

  • 6-Hydroxymethylacylfulvene
  • Adult
  • Human tumor cloning assay
  • MGI 114
  • Pediatric

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Hidalgo, M., Izbicka, E., Eckhardt, S. G., Macdonald, J. R., Cerna, C., Gomez, L., ... Von Hoff, D. D. (1999). Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units. Anti-Cancer Drugs, 10(9), 837-844.

Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units. / Hidalgo, Manuel; Izbicka, Elzbieta; Eckhardt, S. Gail; Macdonald, John R.; Cerna, Cesario; Gomez, Lionel; Rowinsky, Eric K.; Weitman, Steven D; Von Hoff, Daniel D.

In: Anti-Cancer Drugs, Vol. 10, No. 9, 1999, p. 837-844.

Research output: Contribution to journalArticle

Hidalgo, M, Izbicka, E, Eckhardt, SG, Macdonald, JR, Cerna, C, Gomez, L, Rowinsky, EK, Weitman, SD & Von Hoff, DD 1999, 'Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units', Anti-Cancer Drugs, vol. 10, no. 9, pp. 837-844.
Hidalgo, Manuel ; Izbicka, Elzbieta ; Eckhardt, S. Gail ; Macdonald, John R. ; Cerna, Cesario ; Gomez, Lionel ; Rowinsky, Eric K. ; Weitman, Steven D ; Von Hoff, Daniel D. / Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units. In: Anti-Cancer Drugs. 1999 ; Vol. 10, No. 9. pp. 837-844.
@article{a228bd89323b466e966ed60faaad0ff5,
title = "Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units",
abstract = "MGI 114 (6-hydroxymethylacylfulvene, HMAF) is a novel semisynthetic antitumor compound derived from the sesquiterpene mushroom toxin illudin S. Although illudins did not demonstrate significant activity as antiproliferative agents in tumor-bearing animals, several properties including its potent inhibition of DNA synthesis and a unique interaction with DNA led to a structure-activity-based synthetic effort to obtain analogs with improved therapeutic potential. MGI 114 was selected for further development based on its antitumor activity in numerous preclinical tests. MGI 114 was evaluated against adult and pediatric human tumors taken directly from cancer patients and cultured in a human tumor colony-forming assay (HTCFA) to assess the antitumor spectra, concentration-response relationship, schedule dependence and activity of this agent against tumors considered resistant to conventional anticancer drugs. Human tumor colony-forming units were treated with HMAF at concentrations of 0.001, 0.01, 0.1 and 1 μg/ml, both as a 1 h exposure and as a continuous 14 day exposure. A response was scored if there was 50{\%} or less colony survival. In vitro response rates in the range of 50-80{\%} were observed against tumor colony-forming units originating from carcinomas of the colon, kidney, breast, lung cancer, ovary and melanoma. MGI 114 also demonstrated antitumor activity against neuroblastoma colony-forming units. Antitumor activity was not influenced by exposure time as demonstrated by the similar responses rates obtained with the 1 h and continuous exposure at all concentrations tested. However, there was a significant positive concentration-response relationship to both exposure duration with responses increasing from below 10{\%} at the lowest concentration to over 70{\%} at the highest concentration, except for the pediatric tumors on the 1 h exposure for which this relationship was less apparent. At the higher concentration tested, MGI 114 displayed substantial antiproliferative effects in the range of 70{\%} against tumor specimens resistant to classic cytotoxic agents including irinotecan, paclitaxel, 5-fluorouracil, cisplatin, doxorubicin and cyclophosphamide. These results demonstrate that MGI 114 exhibits a broad spectrum of antitumor activity against both adult and pediatric primary tumor colony-forming units in a concentration-dependent manner both at short and prolonged exposure duration. The substantial in vitro activity of MGI 114 at concentrations achievable in clinical trials, together with its activity against tumors resistant to classic standard cytotoxic drugs, justifies the further clinical evaluation of this unique agent.",
keywords = "6-Hydroxymethylacylfulvene, Adult, Human tumor cloning assay, MGI 114, Pediatric",
author = "Manuel Hidalgo and Elzbieta Izbicka and Eckhardt, {S. Gail} and Macdonald, {John R.} and Cesario Cerna and Lionel Gomez and Rowinsky, {Eric K.} and Weitman, {Steven D} and {Von Hoff}, {Daniel D.}",
year = "1999",
language = "English (US)",
volume = "10",
pages = "837--844",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units

AU - Hidalgo, Manuel

AU - Izbicka, Elzbieta

AU - Eckhardt, S. Gail

AU - Macdonald, John R.

AU - Cerna, Cesario

AU - Gomez, Lionel

AU - Rowinsky, Eric K.

AU - Weitman, Steven D

AU - Von Hoff, Daniel D.

PY - 1999

Y1 - 1999

N2 - MGI 114 (6-hydroxymethylacylfulvene, HMAF) is a novel semisynthetic antitumor compound derived from the sesquiterpene mushroom toxin illudin S. Although illudins did not demonstrate significant activity as antiproliferative agents in tumor-bearing animals, several properties including its potent inhibition of DNA synthesis and a unique interaction with DNA led to a structure-activity-based synthetic effort to obtain analogs with improved therapeutic potential. MGI 114 was selected for further development based on its antitumor activity in numerous preclinical tests. MGI 114 was evaluated against adult and pediatric human tumors taken directly from cancer patients and cultured in a human tumor colony-forming assay (HTCFA) to assess the antitumor spectra, concentration-response relationship, schedule dependence and activity of this agent against tumors considered resistant to conventional anticancer drugs. Human tumor colony-forming units were treated with HMAF at concentrations of 0.001, 0.01, 0.1 and 1 μg/ml, both as a 1 h exposure and as a continuous 14 day exposure. A response was scored if there was 50% or less colony survival. In vitro response rates in the range of 50-80% were observed against tumor colony-forming units originating from carcinomas of the colon, kidney, breast, lung cancer, ovary and melanoma. MGI 114 also demonstrated antitumor activity against neuroblastoma colony-forming units. Antitumor activity was not influenced by exposure time as demonstrated by the similar responses rates obtained with the 1 h and continuous exposure at all concentrations tested. However, there was a significant positive concentration-response relationship to both exposure duration with responses increasing from below 10% at the lowest concentration to over 70% at the highest concentration, except for the pediatric tumors on the 1 h exposure for which this relationship was less apparent. At the higher concentration tested, MGI 114 displayed substantial antiproliferative effects in the range of 70% against tumor specimens resistant to classic cytotoxic agents including irinotecan, paclitaxel, 5-fluorouracil, cisplatin, doxorubicin and cyclophosphamide. These results demonstrate that MGI 114 exhibits a broad spectrum of antitumor activity against both adult and pediatric primary tumor colony-forming units in a concentration-dependent manner both at short and prolonged exposure duration. The substantial in vitro activity of MGI 114 at concentrations achievable in clinical trials, together with its activity against tumors resistant to classic standard cytotoxic drugs, justifies the further clinical evaluation of this unique agent.

AB - MGI 114 (6-hydroxymethylacylfulvene, HMAF) is a novel semisynthetic antitumor compound derived from the sesquiterpene mushroom toxin illudin S. Although illudins did not demonstrate significant activity as antiproliferative agents in tumor-bearing animals, several properties including its potent inhibition of DNA synthesis and a unique interaction with DNA led to a structure-activity-based synthetic effort to obtain analogs with improved therapeutic potential. MGI 114 was selected for further development based on its antitumor activity in numerous preclinical tests. MGI 114 was evaluated against adult and pediatric human tumors taken directly from cancer patients and cultured in a human tumor colony-forming assay (HTCFA) to assess the antitumor spectra, concentration-response relationship, schedule dependence and activity of this agent against tumors considered resistant to conventional anticancer drugs. Human tumor colony-forming units were treated with HMAF at concentrations of 0.001, 0.01, 0.1 and 1 μg/ml, both as a 1 h exposure and as a continuous 14 day exposure. A response was scored if there was 50% or less colony survival. In vitro response rates in the range of 50-80% were observed against tumor colony-forming units originating from carcinomas of the colon, kidney, breast, lung cancer, ovary and melanoma. MGI 114 also demonstrated antitumor activity against neuroblastoma colony-forming units. Antitumor activity was not influenced by exposure time as demonstrated by the similar responses rates obtained with the 1 h and continuous exposure at all concentrations tested. However, there was a significant positive concentration-response relationship to both exposure duration with responses increasing from below 10% at the lowest concentration to over 70% at the highest concentration, except for the pediatric tumors on the 1 h exposure for which this relationship was less apparent. At the higher concentration tested, MGI 114 displayed substantial antiproliferative effects in the range of 70% against tumor specimens resistant to classic cytotoxic agents including irinotecan, paclitaxel, 5-fluorouracil, cisplatin, doxorubicin and cyclophosphamide. These results demonstrate that MGI 114 exhibits a broad spectrum of antitumor activity against both adult and pediatric primary tumor colony-forming units in a concentration-dependent manner both at short and prolonged exposure duration. The substantial in vitro activity of MGI 114 at concentrations achievable in clinical trials, together with its activity against tumors resistant to classic standard cytotoxic drugs, justifies the further clinical evaluation of this unique agent.

KW - 6-Hydroxymethylacylfulvene

KW - Adult

KW - Human tumor cloning assay

KW - MGI 114

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=0033429321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033429321&partnerID=8YFLogxK

M3 - Article

C2 - 10587294

AN - SCOPUS:0033429321

VL - 10

SP - 837

EP - 844

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -